BNF for Children April 2025 Update

This update contains 7 significant changes, 2 dose changes, 2 new monographs, and 1 deleted monograph.

Significant Changes:

• Anaemia, iron deficiency: updated guidance for oral iron.
• Emtricitabine with tenofovir alafenamide: new indication and dose for pre-exposure prophylaxis of HIV-1.
• GLP-1 and dual GIP/GLP-1 receptor agonists: potential risk of pulmonary aspiration during general anaesthesia or deep sedation [MHRA/CHM advice] (advice in dulaglutide, liraglutide, semaglutide; see example in liraglutide).
• Immunisation schedule: updated guidance for immunisation against diphtheria, tetanus, pertussis and poliomyelitis in children aged 3 years and 4 months.
• Oral iron: indications and doses updated for iron-deficiency anaemia (advice in ferrous sulfate, ferrous fumarate, ferrous gluconate, sodium feredetate; see example in ferrous sulfate).
• Sodium valproate: new advice for male patients already taking sodium valproate [MHRA/CHM advice].
• Valproic acid: new advice for male patients already taking valproic acid [MHRA/CHM advice].

Dose Changes:

• Dupilumab [update to dosing].
• Evinacumab [update to dosing].

New Monographs:

• Agamree® [vamorolone].
• Joenja® [leniolisib].

Deleted Monographs: Ferrous sulfate with folic acid.